CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 52 enrolled
Drug / intervention
64Cu-SAR-bisPSMAdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05249127
NCT05249127Phase 2Completed
CompareCT.gov

64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 1/2 Study of Participants With Biochemical Recurrence of Prostate Cancer

Clarity Pharmaceuticals Ltd·interventional·Posted Feb 21, 2022·Updated Oct 1, 2024

In Brief

A Phase 2 clinical trial evaluating 64Cu-SAR-bisPSMA for Biochemical Recurrence of Malignant Neoplasm of Prostate. Completed, enrolled 52 participants across 5 sites.

Detailed Summary

The aim of this study is to determine the safety and efficacy of 64Cu-SAR-bisPSMA and determine the ability of 64Cu-SAR-bisPSMA Positron emission tomography (PET)/computed tomography (CT) to correctly detect the recurrence of prostate cancer in participants with biochemical recurrence of prostate cancer following definitive therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBiochemical Recurrence of Malignant Neoplasm of Prostate
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2023202420252026
First PostedFeb 21, 2022
Enrollment StartApr 11, 2022
Primary CompletionAug 8, 2023
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 4.4 years ago

Interventions

64Cu-SAR-bisPSMAdrug

64Cu-SAR-bisPSMA